CD274 and breast carcinoma: Moreover, EV PD-L1 transport PD-L1 to the breast cancer cells with low PD-L1 level 15, suggesting that suppressing EV PD-L1 not only enhances the efficacy of the anti-PD-L1 antibody but also impedes immune evasion by inhibiting PD-L1 transfer to other cells.